A carregar...
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma
Checkpoint inhibitors targeted at programmed cell death‐1 receptor (PD‐1) and its ligand (PD‐L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid t...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058337/ https://ncbi.nlm.nih.gov/pubmed/29674442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0561 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|